Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Candesartan cilexetil/hydrochlorothiazide - Takeda

Next Previous
X
Search
Drug Profile

Candesartan cilexetil/hydrochlorothiazide - Takeda

Alternative Names: Atacand HCT; Atacand Plus; Blopress Plus; CoKenzen; ECARD HD; ECARD LD; Parapres Plus 32; Parapres Plus Forte; TCV-116C

Latest Information Update: 11 Jan 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Developer AstraZeneca; Takeda
  • Class Antihypertensives; Benzimidazoles; Benzothiadiazines; Biphenyl compounds; Heart failure therapies; Tetrazoles
  • Mechanism of Action Angiotensin type 2 receptor antagonists; Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 11 Jan 2021 Candesartan cilexetil licensed to Cheplapharm Arzneimittel in Angola, Argentina, Aruba, Australia, Bahamas, Bahrain, Bermuda, Barbados, Benin, Botswana, Brazil, Brunei Darussalam, Burkina Faso, Cameroon, Canada, Cayman Islands, Chile, Colombia, Congo, Costa Rica, Curaçao, Côte D'Ivoire, Djibouti, Dominican Republic, Ecuador, Egypt, El Salvador, Gabon, Georgia, Ghana, Guatemala, Guinea, Haiti, Honduras, Iraq, Jamaica, Jordan, Kenya, Republic of Korea, Kuwait, Lebanon, Libya, Madagascar, Malaysia, Mali, Mauritania, Mauritius, Mexico, Namibia, New Zealand, Nicaragua, Niger, Nigeria, Oman, Palestine, Panama, Peru, Qatar, Russian Federation, Saudi Arabia, Senegal, Singapore, South Africa, Sri Lanka, Sudan, Togo, Trinidad and Tobago, Tunisia, Turkey, Ukraine, United Arab Emirates, Uruguay and Yemen for marketing
  • 30 Oct 2020 AstraZeneca announces of its decision to divest commercial rights to candesartan cilexetil to Cheplapharm Arzneimittel GmbH
  • 24 Jul 2018 Cheplapharm Arzneimittel acquires commercial rights to candesartan cilexetil/hydrochlorothiazide for Hypertension in Europe

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top